LB Pharmaceuticals Inc Common Stock (NASDAQ: LBRX) is a Healthcare company (Biotechnology) with a market capitalization of $1.3B. The Maz Rating grades it against the other companies in its sector.
LB Pharmaceuticals Inc Common Stock's current Maz Rating and its five factor grades are for members: log in to see them.
At $40.30, LB Pharmaceuticals Inc Common Stock trades at 3.1x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -39.5%, return on invested capital of -35.9% and a free cash flow yield of -11.0%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 14.78. Over the past 52 weeks the share price ranged from $15.19 to $50.16, with a beta of 0.42.
LB Pharmaceuticals Inc Common Stock does not currently pay a dividend.
4 Wall Street analyst ratings cover the stock: 3 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, LB Pharmaceuticals Inc Common Stock (LBRX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 31.4% / 30% · Interest income / Revenue 377100000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 31.4% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 377100000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 31.4% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 377100000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.10% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 91.5% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 377100000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 89.1% / 33.33% · (Cash+Recv) / Total Assets 89.1% / 33.33% · Interest income / Revenue 377100000.0% / 5% | Fail |
No. As of September 2026, LB Pharmaceuticals Inc Common Stock (LBRX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. LB Pharmaceuticals Inc Common Stock is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 377100000.0% of each dividend: LB Pharmaceuticals Inc Common Stock's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.